A股異動 | 立訊精密漲4.68% 股權激勵彰顯發展信心
格隆匯12月6日丨立訊精密漲4.68%,報31.57元,總市值2241億元。公司昨晚發佈2022年股票期權激勵計劃草案,擬向激勵對象授予17,202.10萬份股票期權,授予期權行權價格為30.35元。光大證券隨後發佈研報稱,此次激勵費用攤銷合計16.64億元,相對公司淨利潤近百億體量影響較小,且此次激勵計劃將有效調動高管及核心骨幹員工積極性,將公司利益與員工深度綁定,有助於公司長遠發展。公司積極佈局消費電子、通信、汽車、XR等領域,預計22年度業績將實現歸母淨利潤95.45-98.99億元,同比增長35%-40%,實現扣非歸母淨利潤92.19-96.13億元,同比增長53.26%-59.80%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.